이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Chinese and Australian bio companies mulling IPOs at Korean stock market
- Collected
- 2016.03.10
- Distributed
- 2016.03.11
- Source
- Go Direct
According to the financial investment industry and the Korea Exchange (KRX) on Wednesday, three Chinese healthcare companies including Triplex International Biosciences Co. (TIB) are seeking to go public in the technology and bio-laden Kosdaq market within the year. Shinhan Investment Corp. was hired to proceed with the plan for all three initial public offerings (IPO). Several other Chinese companies have so far been listed in the local stock market, but it would be their first entry in the bio and healthcare segment.
TIB is a Chinese company that develops diagnostic kits for breast cancer. Korea’s private equity fund Stic Investments Inc. invested about 15 billion won ($12 million) in 2010 to own a 7 percent stake in TIB. The other two companies are a living organism feed developer and medicinal herb seller.
An Australian healthcare company is also predicted to go public in the Korean stock market for the first time as early as next year. Elastagen that claims to be the first and only provider of clinical-grade human tropoelastin with unique physical elastic properties effective on cell growth and tissue repair already secured $5 million from Korean venture capital companies to fund its IPO.
“We’ve been receiving a lot of attention from overseas bio companies. We plan to make our bourse a hub for biomedicine and healthcare stocks,” said Hong Soon-wook, an official of the Kosdaq market headquarters.
By Yong Hwan-jin
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]